Lilly (LLY.US) recommends Elpida peptide as a weight loss drug by the UK regulatory agency.
The UK's National Institute for Health and Care Excellence has officially recommended the GLP-1 drug Tirzepatide from Lilly as a weight loss medication.
The UK's drug cost-effectiveness watchdog, the National Institute for Health and Care Excellence (NICE), has formally recommended Eli Lilly and Company's GLP-1 drug Tirzepatide as a weight loss medication. The drug is sold under the names Zepbound for weight loss and Moujaro for treating type 2 diabetes.
Due to anticipated high demand, NICE had earlier stated in December that Tirzepatide would be rolled out over a three-year period, with the "highest clinical need" patients being given priority for the drug.
Related Articles
US Stock Market Move | Nokia Oyj Sponsored ADR (NOK.US) rises 2% and establishes a new artificial intelligence department.
US Stock Market Move | Most new energy vehicle stocks are on the rise, with Lucid Group (LCID.US) up more than 8%.
Meta's annual Connect conference will release AI smart glasses. Zuckerberg is betting big on the smart hardware track.
US Stock Market Move | Nokia Oyj Sponsored ADR (NOK.US) rises 2% and establishes a new artificial intelligence department.
US Stock Market Move | Most new energy vehicle stocks are on the rise, with Lucid Group (LCID.US) up more than 8%.
Meta's annual Connect conference will release AI smart glasses. Zuckerberg is betting big on the smart hardware track.
